Clintec Nutrition Company

Nestec Ltd

W Bruce Rowe

David C Madsen

Susan L Trimbo

David A Mark

Dennis I Goldberg

M Umberto Bracco

James P Martucci

Roger D Clemens

Irene Wei

A method is provided for increasing and/or maintaining the level of intracellular glutathione. Pursuant to the invention, compositions including denatured and at least partially hydrolyzed proteins are administered to a patient in an amount sufficient to increase glutathione levels in the patient.

Method for insuring adequate intracellular glutathione in tissue

The present invention provides a method for reducing and controlling antigen-specific immunoglobulin concentrations in a patient. In addition, the present invention provides a method for maintaining physiological functions of the intestine in a patient. Pursuant to the present invention, the composition includes a protein source, a carbohydrate source, a fat source, and a specialized vitamin and mineral profile.

Method for reducing and controlling immunoglobulin concentrations

The present invention provides a method of treating a viral infection or immune disorder as well as a composition for same. The method of treatment comprises administering to a patient having a viral infection or immune disorder a therapeutically effective amount of a composition including an intracellular glutathione stimulator and an omega-3 fatty acid source.

Method and composition for treating immune disorders, inflammation and

A method for stimulating the intracellular synthesis of glutathione comprising the step of administering to a mammal a therapeutically effective amount of an ester of 2-oxothiazolidine-4-carboxylate is provided.

Method for stimulating intracellular synthesis of glutathione using

The present invention relates to nutrient compositions containing dipeptides and methods for administering the same. In particular, according to the present invention, a nutrient composition comprising an aqueous solution having at least one dipeptide with an N-terminal amino acid selected from the class consisting of glutamine, asparagine, tyrosine, tryptophan, and aspargine is provided. Glutamine (4.8 grams/100 ml at 30.degree. C.), asparagine (3.5 grams/100 mL at 28.degree. C.), tyrosine (0.45 grams/100 mL at 25.degree. C.) and tryptophan (11.4 grams/100 mL at 25.degree. C.) and arginine (15.0 grams/100 mL at 21.degree. C.) are all less soluble in water than glycine (25 grams/100 mL at 25.degree. C.). The C-terminal amino acid is selected from the group consisting of alanine, glycine, tryptophan, arginine, proline and serine. The nutritional solutions contain from about 0.1 to 25.0 percent by weight of oligopeptides, preferably about 0.5 to 5.0 percent by weight.

Nutrient compositions containing peptides and method for administering

An enteral diet for patients with pulmonary disease comprising not less than 18% of said calories from a high quality protein source; from about 20 to 50% of said calories from a slowly metabolizable carbohydrate source derived from maltodextrin or other partially hydrolyzed polysaccharides; from about 40-55% calories from a mixture of lipids comprising medium and long chain triglycerides.

Enteral diet for patients with pulmonary disease

A composition comprising arginine enriched whey protein can be used in the formulation of a variety of simulated food products to provide a substantially fat free, calorie controlled diet which delivers high levels of protein having a hypocholesterolemic amino acid profile.

Enteral diet

The present invention provides a method for treating and/or reducing ischemic reperfusion injury. To this end, in embodiment, a method for treating and/or reducing reperfusion injury is provided comprising the step of administering to a patient in danger of reperfusion injury a therapeutically effective amount of L-2-oxothiazolidine-4-carboxylic acid. In an embodiment, a method is provided for limiting an expected ischemic reperfusion injury comprising the step of administering prior to an expected ischemic event a therapeutically effective amount of L-2-oxothiazolidine-4-carboxylic acid. In a further embodiment of the present invention, a method is provided for limiting ischemic reperfusion injury comprising the step of administering to a patient after the onset of an ischemic event a therapeutically effective amount of L-2-oxothiazolidine-4-carboxylic acid.

Growing community of inventors

Evanston, IL, United States of America

W Bruce Rowe